{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:41Z","timestamp":1790794781843,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["Inca-421 ARC_13566"],"award-info":[{"award-number":["Inca-421 ARC_13566"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["Inca-421 ARC_13566"],"award-info":[{"award-number":["Inca-421 ARC_13566"]}],"id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is a strong rational of using anti\u2013programmed cell death protein-1 and its ligand (anti\u2013PD-1\/L1) antibodies in human papillomavirus (HPV)\u2013induced cancers. However, anti\u2013PD-1\/L1 as monotherapy induces a limited number of objective responses. The development of novel combinations in order to improve the clinical efficacy of an anti\u2013PD-1\/L1 is therefore of interest. Combining anti\u2013PD-1\/L1 therapy with an antitumor vaccine seems promising in HPV-positive (+) cancers. UCPVax is a therapeutic cancer vaccine composed of two separate peptides derived from telomerase (hTERT, human telomerase reverse transcriptase). UCPVax is being evaluated in a multicenter phase I\/II study in NSCLC (non\u2013small cell lung cancer) and has demonstrated to be safe and immunogenic. The aim of the VolATIL study is to evaluate the combination of atezolizumab (an anti-PD-L1) and UCPVax vaccine in a multicenter phase II study in patients with HPV<jats:sup>+<\/jats:sup> cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with HPV<jats:sup>+<\/jats:sup> cancer (anal canal, head and neck, and cervical or vulvar), at locally advanced or metastatic stage, and refractory to at least one line of systemic chemotherapy are eligible. The primary end point is the objective response rate (ORR) at 4 months. Patients will receive atezolizumab every 3 weeks at a fixed dose of 1,200 mg in combination with the UCPVax vaccine at 1 mg subcutaneously.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Anti-cancer vaccines can restore cancer-immunity <jats:italic>via<\/jats:italic> the expansion and activation of tumor-specific T cells in patients lacking pre-existing anti-tumor responses. Moreover, preclinical data showed that specific T<jats:sub>H<\/jats:sub>1 CD4 T cells sustain the quality and homing of an antigen-specific CD8<jats:sup>+<\/jats:sup> T-cell immunity. In previous clinical studies, the induction of anti-hTERT immunity was significantly correlated to survival in patients with advanced squamous anal cell carcinoma. Thus, there is a strong rational to combine an anti-cancer hTERT vaccine and an immune checkpoint inhibitor to activate and promote antitumor T-cell immunity. This pivotal proof of concept study will evaluate the efficacy and safety of the combination of a telomerase-based T<jats:sub>H<\/jats:sub>1 inducing vaccine (UCPVax) and an anti\u2013PD-L1 (atezolizumab) immunotherapy in HPV<jats:sup>+<\/jats:sup> cancers, as well as confirming their synergic mechanism, and settling the basis for a new combination for future clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.clinicaltrials.gov\/<\/jats:uri>, identifier NCT03946358.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.957580","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T06:53:55Z","timestamp":1658213635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Magali","family":"Rebucci-Peixoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Vienot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Adotevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Jacquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Maurina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Clairet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fagnoni-Legat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Spehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Bouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Meurisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human Papillomavirus DNA Prevalence and Type Distribution in Anal Carcinomas Worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ijc.28201","article-title":"Eurogin Roadmap: Comparative Epidemiology of HPV Infection and Associated Cancers of the Head and Neck and Cervix","volume":"134","author":"Gillison","year":"2014","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"JCO"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.09.049","article-title":"Anal Squamous Cell Carcinoma: Radiation Therapy Alone Must Be Avoided","volume":"247","author":"Almaazmi","year":"2020","journal-title":"J Surg Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.9.4467-4472.2001","article-title":"Transcriptional Activation of the Telomerase hTERT Gene by Human Papillomavirus Type 16 E6 Oncoprotein","volume":"75","author":"Veldman","year":"2001","journal-title":"J Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01318-08","article-title":"Cell-Restricted Immortalization by Human Papillomavirus Correlates With Telomerase Activation and Engagement of the hTERT Promoter by Myc","volume":"82","author":"Liu","year":"2008","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, Cisplatin, and Fluorouracil Chemotherapy for Metastatic or Unresectable Locally Recurrent Anal Squamous Cell Carcinoma (Epitopes-HPV02): A Multicentre, Single-Arm, Phase 2 Study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920975356","article-title":"Pooled Analysis of 115 Patients From Updated Data of Epitopes-HPV01 and Epitopes-HPV02 Studies in First-Line Advanced Anal Squamous Cell Carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3122","article-title":"Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells","volume":"180","author":"Wong","year":"2008","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","article-title":"CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness","volume":"47","author":"Ahrends","year":"2017","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.3390\/cancers13153895","article-title":"Present and Future Research on Anal Squamous Cell Carcinoma","volume":"13","author":"Spehner","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3185","article-title":"Analysis of Spontaneous Tumor-Specific CD4 T-Cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect With Chemotherapy Response","volume":"18","author":"Godet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3939","article-title":"Gene Expression Patterns Through Oral Squamous Cell Carcinoma Development: PD-L1 Expression in Primary Tumor and Circulating Tumor Cells","volume":"6","author":"Oliveira-Costa","year":"2015","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02754-x","article-title":"PD-1 Blockade Synergizes With Intratumoral Vaccination of a Therapeutic HPV Protein Vaccine and Elicits Regression of Tumor in a Preclinical Model","volume":"70","author":"Peng","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): A Multicentre, Single-Arm, Phase 2 Study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients With Recurrent Carcinoma of the Anal Canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for Previously Treated Advanced Anal Squamous Cell Carcinoma: Pooled Results From the KEYNOTE-028 and KEYNOTE-158 Studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"JCO"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2272","article-title":"LBA42 POD1UM-202: Phase II Study of Retifanlimab in Patients (Pts) With Squamous Carcinoma of the Anal Canal (SCAC) Who Progressed Following Platinum-Based Chemotherapy","volume":"31","author":"Rao","year":"2020","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":":e002996","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized Phase II Trial of Avelumab Alone or in Combination With Cetuximab for Patients With Previously Treated, Locally Advanced, or Metastatic Squamous Cell Anal Carcinoma: The CARACAS Study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1\u2013Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"JCO"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"JCO"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and Safety of Pembrolizumab in Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma: Pooled Analyses After Long-Term Follow-Up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.513","article-title":"402mo Final Results of the CARACAS Study: Randomized Phase II Trial of Avelumab Alone or With Cetuximab for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma Progressed to at Least One Line of Treatment","volume":"31","author":"Lonardi","year":"2020","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.957580\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T06:53:57Z","timestamp":1658213637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.957580\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":27,"alternative-id":["10.3389\/fonc.2022.957580"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.957580","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"article-number":"957580"}}